DXY is China's foremost digital health technology company. Since founding in 2000, DXY has garnered 9 million registered healthcare professionals ? around 80% of China's medical workforce, including 4.05 million licensed physicians, representing around 92% of all licensed physicians in China.

Founded in 2006, DXY Insight Database is a global pharmaceutical data intelligence and analytics platform developed by DXY. With 20 years' continuous development in the pharmaceutical sector, we serve 3,000+ enterprises across the full industry value chain, including pharmaceutical companies, investment firms, and pharmaceutical service providers.

We are trusted by leading industry players, including 92% of MNCs and 75% of China’s Top 100 pharmaceutical enterprises. As a long-term data partner to the industry, it enables organizations to quickly understand competitive landscapes, identify emerging opportunities, and make more informed decisions in new drug R&D strategy and pipeline development.

DXY Insight Database provides global pharmaceutical full-lifecycle data with deep China insights, which is 100% verifiable and fully traceable. We aim to engage with potential partners, including pharmaceutical companies, biotech innovators, investment institutions and consulting firms, who seek to make more precise decisions and work more efficiently, particularly in BD and transaction decision-making.

We enable partners to gain comprehensive visibility into global drug pipelines and competitive landscapes, and to identify and evaluate high-value assets across therapeutic areas. By integrating multi-dimensional insights, users can better assess in-licensing and out-licensing opportunities and improve the efficiency and accuracy of BD evaluation and strategic partnering decisions.